Scarica l'app Stockscreener
0.6846
2.20%
-0.0154
Dopo l'orario di chiusura:
.69
0.0054
+0.79%
Precedente Chiudi:
$0.70
Aprire:
$0.7
Volume 24 ore:
211.72K
Relative Volume:
0.38
Capitalizzazione di mercato:
$35.48M
Reddito:
-
Utile/perdita netta:
$-81.22M
Rapporto P/E:
-0.2313
EPS:
-2.96
Flusso di cassa netto:
$-74.41M
1 W Prestazione:
+3.16%
1M Prestazione:
-1.74%
6M Prestazione:
-23.26%
1 anno Prestazione:
-24.76%
Intervallo 1D:
$0.6801
$0.7049
Intervallo di 1 settimana:
$0.6502
$0.71
Portata 52W:
$0.615
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
Nome
Xilio Therapeutics Inc
Settore
Industria
Telefono
617-833-1027
Indirizzo
828 WINTER STREET, WALTHAM
Confronta XLO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.6846 | 36.28M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Iniziato | Leerink Partners | Outperform |
| 2022-12-21 | Iniziato | Chardan Capital Markets | Buy |
| 2022-01-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-16 | Iniziato | Cowen | Outperform |
| 2021-11-16 | Iniziato | Guggenheim | Buy |
| 2021-11-16 | Iniziato | Morgan Stanley | Overweight |
| 2021-11-16 | Iniziato | Raymond James | Outperform |
Mostra tutto
Xilio Therapeutics Inc Borsa (XLO) Ultime notizie
Should you wait for a breakout in Xilio Therapeutics Inc.July 2025 EndofMonth & Risk Controlled Daily Trade Plans - Newser
Can momentum traders help lift Xilio Therapeutics Inc.CEO Change & Weekly Return Optimization Alerts - Newser
Risk adjusted return profile for Xilio Therapeutics Inc. analyzedEarnings Overview Report & Real-Time Buy Zone Alerts - Newser
How to use Fibonacci retracement on Xilio Therapeutics Inc.Quarterly Profit Review & AI Powered Market Trend Analysis - Newser
Using Bollinger Bands to evaluate Xilio Therapeutics Inc.Weekly Trade Summary & Community Consensus Trade Signals - Newser
What makes Xilio Therapeutics Inc. stock price move sharplyEarnings Risk Report & Weekly Top Stock Performers List - Newser
Analyzing net buyer seller activity in Xilio Therapeutics Inc.Portfolio Return Summary & Weekly Stock Breakout Alerts - Newser
Advanced analytics toolkit walkthrough for Xilio Therapeutics Inc.2025 AllTime Highs & Detailed Earnings Play Alerts - Newser
Xilio Therapeutics Inc. Stock Poised for Technical Comeback getLinesFromResByArray error: size == 0 - 더경남뉴스
Can you recover from losses in Xilio Therapeutics Inc.2025 Stock Rankings & Technical Pattern Based Signals - Newser
What to do if you’re stuck in Xilio Therapeutics Inc.Earnings Summary Report & High Accuracy Buy Signal Tips - Newser
Xilio Therapeutics Inc. Shows Early Signs of Technical Strength getLinesFromResByArray error: size == 0 - kangso.co.kr
Can Xilio Therapeutics Inc. rally from current levels2025 AllTime Highs & Verified Short-Term Plans - Newser
Visual trend scoring systems applied to Xilio Therapeutics Inc.Oil Prices & Reliable Entry Point Trade Alerts - Newser
What indicators show strength in Xilio Therapeutics Inc.July 2025 Momentum & Community Supported Trade Ideas - Newser
Xilio Therapeutics Inc. Enters Reversal Setup in Weekly ChartsStop Loss & Precise Entry and Exit Recommendations - newsyoung.net
Analyzing drawdowns of Xilio Therapeutics Inc. with statistical toolsShare Buyback & Consistent Return Strategy Ideas - Newser
How to read the order book for Xilio Therapeutics Inc.Trade Risk Report & Safe Entry Trade Signal Reports - Newser
Can Xilio Therapeutics Inc. deliver consistent dividendsTrade Performance Summary & Verified Momentum Stock Ideas - theviewers.co.kr
Moving Averages: Does Xilio Therapeutics Inc. have strong fundamentals2025 Winners & Losers & Community Consensus Trade Alerts - theviewers.co.kr
Is Xilio Therapeutics Inc.’s ROE strong enough2025 Geopolitical Influence & Weekly High Return Stock Opportunities - theviewers.co.kr
Technical Models Suggest Xilio Therapeutics Inc. May Rebound Soon2025 Market Overview & Expert Verified Movement Alerts - mustnews.co.kr
Xilio Therapeutics' Q2 Earnings Show Promising Pipeline Progress and Strong Financial Position - AInvest
Xilio Therapeutics Reports Strong Pipeline Progress and Financial Results - The Globe and Mail
Technical analysis overview for Xilio Therapeutics Inc. stockWeekly Trade Summary & AI Optimized Trading Strategy Guides - Newser
Can trapped investors hope for a rebound in Xilio Therapeutics Inc.Quarterly Portfolio Summary & Growth Oriented Trading Recommendations - Newser
Xilio Therapeutics Reports Q2 Earnings with Promising Pipeline Progress and Financial Results - AInvest
Xilio Therapeutics Q2 2025 Earnings Miss Fails to Deliver, but Short-Term Price Action Shows Promise - AInvest
Xilio Therapeutics Q2 2025 Earnings Miss: Mixed Market Impact Amid Biotech Sector Resilience - AInvest
Will Xilio Therapeutics Inc. rebound enough to break evenWeekly Loss Report & Daily Chart Pattern Signal Reports - Newser
Does Xilio Therapeutics Inc. align with a passive investing strategy2025 Price Action Summary & Low Risk Investment Opportunities - thegnnews.com
Xilio Therapeutics Second Quarter 2025 Earnings: US$0.16 loss per share (vs US$0.32 loss in 2Q 2024) - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Clover Health Investments (CLOV) and Xilio Therapeutics (XLO) - The Globe and Mail
Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates - MSN
Xilio Therapeutics shares fall 1.27% after-hours following Q2 pipeline progress and business updates. - AInvest
Xilio Revenue Jumps 246 Percent in Q2 - AOL.com
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results - MarketScreener
Xilio Therapeutics 2025 Q2 Earnings Improved EPS Amid Wider Net Loss - AInvest
Xilio Therapeutics Q2 Earnings Beat Expectations, Revenue Doubles to $8.084M. - AInvest
Xilio Therapeutics shares fall 2.52% intraday after announcing updated Phase 2 data for vilastobart. - AInvest
Xilio Therapeutics Reports Q2 Loss, Misses Revenue Estimates: Stock Expected to Underperform Market - AInvest
Xilio Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Xilio Therapeutics, Inc. SEC 10-Q Report - TradingView
Xilio Therapeutics Q2 2025 Financial Results and Business Updates - TradingView
Cancer Drug Breakthrough: Xilio's Vilastobart Delivers Strong Results with Fewer Side Effects - Stock Titan
Xilio Therapeutics Inc Azioni (XLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xilio Therapeutics Inc Azioni (XLO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shannon James Samuel | Director |
Jun 17 '25 |
Buy |
0.69 |
25,000 |
17,215 |
70,000 |
| Russo Rene | PRESIDENT AND CEO |
Jun 16 '25 |
Buy |
0.68 |
36,289 |
24,680 |
281,172 |
| Frankenfield Christopher James | Chief Financial Officer |
Jan 02 '25 |
Sale |
0.98 |
6,954 |
6,841 |
12,421 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING |
Jan 02 '25 |
Sale |
0.98 |
1,803 |
1,774 |
3,197 |
| GILEAD SCIENCES, INC. | 10% Owner |
Dec 18 '24 |
Buy |
1.04 |
1,759,978 |
1,830,377 |
9,105,451 |
0.98%
8.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):